Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study Evaluating the Safety, Tolerability, Biodistribution, Dose Determination, and Preliminary Efficacy of ¹⁷⁷Lu-DOTA-SNA040 in Patients With Claudin 18.2-positive Advanced Solid Tumors

NCT07595237 is registered in ClinicalTrials.gov with SmartNuclide Biopharma as lead sponsor.

NCT NCT07595237
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07595237 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study Evaluating the Safety, Tolerability, Biodistribution, Dose Determination, and Preliminary Efficacy of ¹⁷⁷Lu-DOTA-SNA040 in Patients With Claudin 18.2-positive Advanced Solid Tumors
Lead sponsor
SmartNuclide Biopharma
Phase
Phase 1
Overall status
Recruiting
Start date
November 1, 2025
Completion date
June 1, 2027
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors (such as adenocarcinoma at the gastroesophageal junction), advanced solid tumors (such as cholangiocarcinoma), advanced solid tumors (such as gastric cancer), advanced solid tumors (such as pancreatic cancer)